Terns Pharmaceuticals (Terns Pharmaceuticals) 14-Day RSI : 44.53 (As of Apr. 30, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Terns Pharmaceuticals 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-30), Terns Pharmaceuticals's 14-Day RSI is 44.53.

The industry rank for Terns Pharmaceuticals's 14-Day RSI or its related term are showing as below:

TERN's 14-Day RSI is ranked better than
55.88% of 1573 companies
in the Biotechnology industry
Industry Median: 46.35 vs TERN: 44.53

Competitive Comparison of Terns Pharmaceuticals's 14-Day RSI

For the Biotechnology subindustry, Terns Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Terns Pharmaceuticals's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Terns Pharmaceuticals's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Terns Pharmaceuticals's 14-Day RSI falls into.

Terns Pharmaceuticals (NAS:TERN) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI

100

–

[ 100

( 1 + Average Gain

Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Terns Pharmaceuticals (NAS:TERN) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.

Terns Pharmaceuticals 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Terns Pharmaceuticals's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.

Terns Pharmaceuticals (Terns Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Terns Pharmaceuticals Inc (NAS:TERN) » Definitions » 14-Day RSI

Comparable Companies

Traded in Other Exchanges

430:Germany

Address

1065 East Hillsdale Boulevard, Suite 100, Foster, CA, USA, 94404

Website

https://www.ternspharma.com

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.

Executives

Mark J. Vignola	officer: Chief Financial Officer	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Seokho Bryan Yoon	officer: COO and General Counsel	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Senthil Vel Sundaram	director, officer: Chief Executive Officer	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Vivo Opportunity Fund Holdings, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Hongbo Lu	director	C/O AVEDRO, INC., 201 JONES ROAD, WALTHAM MA 02451
Carl L Gordon	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Lav Biosciences Fund V, L.p.	10 percent owner	C/O ESTERA TRUST (CAYMAN) LIMITED, 75 FORT STREET, PO BOX 1350, GRAND CAYMAN E9 KY1-1108
Lav Aqua Ltd	10 percent owner	UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Hopewell Resources Holdings Ltd	10 percent owner	UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Oriental Spring Venture Ltd	10 percent owner	UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Orbimed Capital Gp Vii Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Iii Ltd	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Asia Gp Iii, L.p.	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629